Doliver Advisors’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
Doliver Advisors's VRDN Position: Q3 2026 in Review
Doliver Advisors sold out of Viridian Therapeutics (VRDN) in Q3 2026, closing a stake of 30,000 shares — an estimated $551K sold.
Doliver Advisors first reported a position in VRDN in Q2 2026 and held it in 1 quarter. The position peaked at $551K in Q2 2026. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Doliver Advisors reported no remaining Viridian Therapeutics position as of Q3 2026 after selling out during the quarter.
- Doliver Advisors sold 30,000 Viridian Therapeutics shares in Q3 2026, an estimated $551K.
- Doliver Advisors first reported a position in Viridian Therapeutics in Q2 2026 and held it in 1 quarter.
- Doliver Advisors's Viridian Therapeutics position peaked at $551K in Q2 2026.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Doliver Advisors's 13F filing for Q3 2026, filed 1 Oct 2026.